- Home
- PMVP vs IVVD Comparison
PMVP vs IVVD Comparison
Compare PMVP & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- IVVD
- Stock Information
- Founded
- PMVP 2013
- IVVD 2020
- Country
- PMVP United States
- IVVD United States
- Employees
- PMVP N/A
- IVVD N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- IVVD Health Care
- Exchange
- PMVP Nasdaq
- IVVD Nasdaq
- Market Cap
- PMVP 77.4M
- IVVD 63.4M
- IPO Year
- PMVP 2020
- IVVD 2021
- Fundamental
- Price
- PMVP $1.25
- IVVD $1.21
- Analyst Decision
- PMVP Strong Buy
- IVVD Strong Buy
- Analyst Count
- PMVP 1
- IVVD 4
- Target Price
- PMVP $5.00
- IVVD $3.64
- AVG Volume (30 Days)
- PMVP 2.7M
- IVVD 14.9M
- Earning Date
- PMVP 11-06-2025
- IVVD 11-13-2025
- Dividend Yield
- PMVP N/A
- IVVD N/A
- EPS Growth
- PMVP N/A
- IVVD N/A
- EPS
- PMVP N/A
- IVVD N/A
- Revenue
- PMVP N/A
- IVVD $46,210,000.00
- Revenue This Year
- PMVP N/A
- IVVD $112.35
- Revenue Next Year
- PMVP N/A
- IVVD $272.14
- P/E Ratio
- PMVP N/A
- IVVD N/A
- Revenue Growth
- PMVP N/A
- IVVD 1941.08
- 52 Week Low
- PMVP $0.81
- IVVD $0.35
- 52 Week High
- PMVP $1.84
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- PMVP 43.13
- IVVD 58.70
- Support Level
- PMVP $1.12
- IVVD $1.15
- Resistance Level
- PMVP $1.35
- IVVD $1.45
- Average True Range (ATR)
- PMVP 0.16
- IVVD 0.16
- MACD
- PMVP -0.03
- IVVD 0.01
- Stochastic Oscillator
- PMVP 17.25
- IVVD 55.66
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.